It is my great pleasure to invite you to The European Congress on Controversies in Lymphoma (Lymphoma2019)
, taking place on 25-26 September 2019 in Amsterdam, The Netherlands.
The past few years have witnessed significant improvements in our understanding of lymphoproliferative malignancies and in our capabilities to treat patients diagnosed with these diseases. The introduction of new agents, including small molecules, non-conjugated and conjugated antibodies, and immunomodulation technologies (particularly chimeric antigen receptor T cells) has considerably changed the landscape of lymphoproliferative malignancies, with most patients achieving at least a durable response and even cure.
The scientific program of the upcoming congress covers topics from all fields of clinical and laboratory aspects of chronic lymphocytic leukemia and lymphoma. World leaders in these fields will take part in this meeting and address new diagnostic technologies, current and future therapies. A special session will also be provided by leading experts in CAR T cells.
I am confident that you will find the scientific program highly informative and enjoyable. The meeting will also provide a unique opportunity to meet colleagues from all over Europe, and serve as a platform for future collaborations.I look forward to welcoming you to The First European Congress on Controversies in Lymphoma (Lymphoma2019) in the majestic, historical and multicultural city of Amsterdam.
Yours Sincerely,Prof. Irit Avivi